A strategic partnership to advance high-throughput RNAi screening
May 23 2006

A strategic partnership to advance high-throughput RNAi screening

May 23, 2006

QIAGEN and CytoPathfinder have announced the formation of a strategic partnership between the two companies to combine their unique technologies in developing advanced tools for high-throughput RNAi screening.

QIAGEN is the recognized market leader in high-throughput siRNA design and synthesis. Its HiPerformance siRNA sets are used in many academic and pharma/biotech labs. CytoPathfinder has developed a unique Transfection Microarray technology (TMA) which allows high-throughput siRNA screening on a microarray chip, significantly reducing workflow complexity and increasing screening efficiency. Both companies have agreed to combine product knowledge and technology platforms to develop new-generation tools for high-throughput RNAi screening.

RNAi is a powerful tool which combines accuracy and efficiency to unravel the functioning of genes in biological systems and pathological conditions. Recent advances have greatly improved siRNA design and led to the synthesis of large sets of siRNAs which target complete gene families or even the whole human genome. These developments have made high-throughput RNAi more accessible to both pharmaceutical companies and academic researchers.

FOLLOW US ON SOCIAL MEDIA

Share this page